Pacific Biosciences (PACB) Stock Statistics & Valuation Metrics

Pacific Biosciences has a market cap or net worth of $411.04M. The enterprise value is $845.63M.

Pacific Biosciences has 297.85M shares outstanding. The number of shares has decreased by -2.65% in one year.

Pacific Biosciences’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -29.63%.

The current PE Ratio of Pacific Biosciences is -1.62. Pacific Biosciences’s PEG ratio is 0.25.

In the last 12 months, Pacific Biosciences had revenue of $154.01M and earned -$309.85M in profits. Earnings per share was -$1.14.

In the last 12 months, operating cash flow was -$206.06M and capital expenditures -$6.19M, giving a free cash flow of -$212.25M billion.

Pacific Biosciences pays an annual dividend of , resulting in a dividend yield of

Pacific Biosciences upcoming earnings date is May 8, 2025, TBA.

Pacific Biosciences as a current ratio of 7.48, with Debt / Equity ratio of 1.33

In the past 12 months, Pacific Biosciences has paid $12.29M in taxes.

Pacific Biosciences EV to EBITDA ratio is -3.14, with an EV/FCF ratio of -5.27.

Pacific Biosciences has $389.93M in cash and marketable securities with $672.43M in debt, giving a net cash position of $282.50M billion.

Gross margin is 24.21%, with operating margin of -231.40%, and net profit margin of -201.18%.

The average price target for Pacific Biosciences is $2.15, which is 11.43% higher than the current price. The consensus rating is Moderate Buy